Clinical Trial Update: Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update examining the efficacy and biomarker explanation of IBI-322 combined with lenvatinib in extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• IBI-322 (IBI-322)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN